Key Highlights

  • Third-quarter Research and Development expenses were USD 612,000, down 65% from a year earlier.
  • Cash and cash equivalents were approximately USD 8.5 million at September 30, 2026.
  • Nine-month net loss attributable to common stockholders was approximately USD 6.7 million.
  • Net cash used in Operating Activities for nine months was USD 8.4 million.

Theriva Biologics (NYSE American:TOVX) reported third-quarter 2026 loss per share of USD 0.03, against an estimate of USD 0.06. The company reported no Revenue for the quarter. Its lead product candidate is VCN-01, also known as zabilugene almadenorepvec, a clinical stage oncolytic human adenovirus modified for tumor-selective replication and to express PH20 hyaluronidase.

The filing describes the enzyme as intended to break down the tumor stroma barrier surrounding the tumor. VCN-01 has been evaluated in the Phase 2b VIRAGE study in pancreatic cancer, a Phase 1 study in retinoblastoma and other Phase 1 studies in solid tumors, including head and neck squamous cell carcinoma.

Research and Development Expenses

Research and development expenses were USD 612,000 for the three months ended September 30, 2026, against approximately USD 2.6 million for the same period of 2025, a decrease of 65%. The filing says this primarily reflects a USD 1.0 million decrease in the Fair Value of contingent consideration recognized in the nine months of 2026, against a USD 9.8 million increase recognized in the same period of 2025, partly offset by higher legal fees in 2026.

For the nine months, research and development expenses were USD 2.2 million, against approximately USD 7.5 million. The stock-based compensation charge in research and development was USD 340,000 for the nine months, against USD 269,000, and USD 119,000 for the quarter, against USD 118,000.

Net Loss and Cash Flow

Net loss attributable to common stockholders was approximately USD 6.7 million, or USD 0.15 per basic and diluted share, for the nine months ended September 30, 2026. The comparison was approximately USD 21.7 million, or USD 3.38 per share, for the same period of 2025.

Net cash used in operating activities was USD 8.4 million for the nine months, against USD 13.8 million a year earlier. The filing attributes the primary use of funds to the development of VCN-01, and the decrease to the prior-year contingent consideration adjustment and lower research costs. Cash, cash equivalents and restricted cash at the end of the period were USD 8,517 thousand, against USD 7,574 thousand a year earlier.

Liquidity and Operating Plans

At September 30, 2026, the company had cash and cash equivalents of approximately USD 8.5 million, and as of early November 2026 it had USD 7.5 million. It had an accumulated Deficit of USD 365.4 million and Working Capital of USD 1.8 million, against an accumulated deficit of USD 358.7 million and working capital of USD 7.5 million at December 31, 2025. Cash and cash equivalents were approximately USD 13.1 million at December 31, 2025.

The filing states that management believes current cash on hand is sufficient to execute its plans into the first quarter of 2027. The financial statements include a Going Concern disclosure: management evaluated conditions that raise substantial doubt about the ability to continue as a going concern within one year of issuance. The filing says this ability depends on raising additional Debt and Equity capital or securing a license or strategic relationship to fund clinical development, and that there can be no assurance that such capital is available.

The company's plans for its current cash include covering overhead costs, completing recruitment into the VIRAGE2 Phase 2a study in metastatic pancreatic cancer evaluating more frequent VCN-01 dosing for a longer period, and conducting exploratory VCN-01 Manufacturing scale-up activities. They also include completing regulatory interactions on a proposed pivotal trial of VCN-01 in retinoblastoma and limited preclinical studies supporting VCN-01 and VCN-12, the first candidate from the VCN-X discovery program. The filing states that it did not have any material finance leases at September 30, 2026.